CRISP REGIONAL HEALTH SERVICES, INC. CORDELE, GEORGIA

COMBINED FINANCIAL STATEMENTS

for the years ended June 30, 2022 and 2021



Let's Think Together."

CONTENTS

	<u>Pages</u>
Independent Auditor's Report	1-2
Combined Financial Statements:	
Balance Sheets	3-4
Statements of Operations and Changes in Net Assets	5
Statements of Cash Flows	6-7
Notes to Combined Financial Statements	8-38
Independent Auditor's Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	39-40
6	



INDEPENDENT AUDITOR'S REPORT

Board of Directors Crisp Regional Health Services, Inc. Cordele, Georgia

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying combined financial statements of Crisp Regional Health Services, Inc. (Corporation), which comprise the combined balance sheets as of June 30, 2022 and 2021, and the related combined statements of operations and changes in net assets, and cash flows for the years then ended, and the related notes to the combined financial statements.

In our opinion, the accompanying combined financial statements present fairly, in all material respects, the financial position of Crisp Regional Health Services, Inc. as of June 30, 2022 and 2021, and the results of operations, changes in net assets, and cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Corporation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the combined financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of combined financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the combined financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern within one year after the date that the combined financial statements are issued.

Continued

1 Let's Think Together.®

Draffin & Tucker, LLP | CPAs and Advisors | www.draffin-tucker.com P.O. Box 71309 | 2617 Gillionville Road | Albany, GA 31708-1309 | (229) 883-7878 5 Concourse Parkway, Suite 1250 | Atlanta, GA 30328 | (404) 220-8494

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the combined financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgement of a reasonable user based on these combined financial statements.

In performing an audit in accordance with generally accepted auditing standards and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the combined financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the combined financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the combined financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 25, 2022, on our consideration of the Corporation's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Corporation's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Corporation's internal control over financial reporting and compliance.

DRAFFIN + TUCKER, MP

Albany, Georgia October 25, 2022

COMBINED BALANCE SHEETS June 30, 2022 and 2021

	2022	<u>2021</u>
ASSETS		
Current assets:		
Cash	\$ 12,160,000	\$ 14,574,000
Assets limited as to use	1,414,000	1,345,000
Patient accounts receivable, net	24,218,000	20,024,000
Estimated third-party payor settlements	-	705,000
Supplies, at lower of cost (first-in, first-out)	2 202 000	2 202 000
and net realizable value Current portion of notes receivable	2,293,000 739,000	2,292,000 758,000
Other current assets	<u> </u>	8,453,000
Other current assets		0,400,000
Total current assets	46,780,000	48,151,000
	<u> </u>	
Assets limited as to use:		
Internally designated for capital improvements	56,451,000	63,142,000
Held by trustee	27,491,000	1,345,000
Externally restricted for collateral	1,002,000	1,001,000
	84,944,000	65,488,000
Less amount required to meet current obligations	1,414,000	1,345,000
Noncurrent assets limited as to use	83,530,000	64,143,000
Property and equipment not	44 010 000	42 222 000
Property and equipment, net	44,910,000	43,232,000
Other assets:		
Notes receivable, net of current portion	348,000	372,000
Goodwill and intangibles, net	9,580,000	10,658,000
Operating lease right-of-use assets	88,000	198,000
Investment in affiliated companies	432,000	432,000
Total other assets	10,448,000	11,660,000
Total assets	\$ <u>185,668,000</u>	\$ <u>167,186,000</u>

COMBINED BALANCE SHEETS, Continued June 30, 2022 and 2021

_

	<u>2022</u>	<u>2021</u>
LIABILITIES AND NET ASSE	TS	
Current liabilities: Current portion of long-term debt Current portion of operating lease liabilities Accounts payable Accrued expenses Estimated third-party payor settlements Medicare advance payments, current portion	\$ 1,764,000 9,000 6,467,000 8,930,000 554,000 <u>3,651,000</u>	\$ 1,994,000 185,000 4,993,000 9,192,000 308,000 4,354,000
Total current liabilities	21,375,000	21,026,000
Medicare advance payments, long-term portion Other liabilities Long-term debt, net of current portion Paycheck Protection Program	50,710,000	3,396,000 574,000 25,626,000 9,265,000
Total liabilities	72,085,000	59,887,000
Net assets without donor restrictions	<u>113,583,000</u>	<u>107,299,000</u>

Total liabilities and net assets

\$ <u>185,668,000</u> \$ <u>167,186,000</u>

See accompanying notes to the combined financial statements.

COMBINED STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS for the years ended June 30, 2022 and 2021

	<u>2022</u>	<u>2021</u>
Revenues, gains and other support: Net patient service revenue Other revenue Grant stimulus funding PPP loan forgiveness	\$ 113,978,000 2,444,000 5,097,000 <u>9,265,000</u>	\$ 106,302,000 2,344,000 5,186,000
Total revenues, gains and other support	<u>130,784,000</u>	<u>113,832,000</u>
Expenses: Professional care of patients Dietary services General services Administrative services Employee health and welfare Depreciation and amortization Interest	$78,346,000 \\ 2,531,000 \\ 5,095,000 \\ 14,590,000 \\ 10,896,000 \\ 6,111,000 \\ 1,543,000$	70,175,000 2,272,000 4,589,000 15,051,000 12,010,000 5,479,000 976,000
Total expenses	<u>119,112,000</u>	<u>110,552,000</u>
Operating income	11,672,000	3,280,000
Other income: Undesignated gifts and bequests Investment income (loss) Loss on refunding Gain on disposal of assets Total other income (loss) Excess revenues	2,086,000 (6,699,000) (778,000) <u>3,000</u> (<u>5,388,000</u>) 6,284,000	1,323,000 8,231,000 - 2,000 9,556,000 12,836,000
Capital contributions	-	134,000
Increase in net assets without donor restrictions	6,284,000	12,970,000
Net assets without donor restrictions, beginning of year	<u>107,299,000</u>	94,329,000
Net assets without donor restrictions, end of year	\$ <u>113,583,000</u>	\$ <u>107,299,000</u>

See accompanying notes to the combined financial statements.

COMBINED STATEMENTS OF CASH FLOWS for the years ended June 30, 2022 and 2021

	<u>2022</u>	<u>2021</u>
Cash flows from operating activities:		
Increase in net assets	\$ 6,284,000	\$ 12,970,000
Adjustments to reconcile increase in net assets to net	Ψ 0,204,000	ψ 12,570,000
cash provided by operating activities:		
Depreciation and amortization	6,111,000	5,479,000
Amortization of debt issuance costs and premium	(225,000)	48,000
Loss on refunding	778,000	40,000
Change in net unrealized (gains) losses on investments	9,847,000	- (5,454,000)
Realized (gains) losses on sales of securities	(2,257,000)	(1,871,000)
Operating lease right-of-use assets	162,000	223,000
(Increase) decrease in:	102,000	223,000
Patient accounts receivable	(4,194,000)	(1,502,000)
Supplies	(1,000)	(101,000)
Other current assets		,
	2,497,000	(6,093,000)
Estimated third-party payor settlements Notes receivable	951,000	(291,000) (27,000)
	43,000	(27,000)
Increase (decrease) in:	0 450 000	(454.000)
Accounts payable	2,153,000	(454,000)
Accrued expenses	(262,000)	2,555,000
Medicare advance payments	(4,099,000)	5,072,000
Operating lease liabilities	(228,000)	(236,000)
PPP loan refundable advance	(<u>9,265,000</u>)	9,265,000
Net cash provided by operating activities	8,295,000	<u>19,583,000</u>
Cash flows from investing activities:		
Purchase of property and equipment and		
intangible assets	(7,777,000)	(11,230,000)
Purchase of investments	(30,665,000)	(51,861,000)
Proceeds from sale of investments	29,878,000	42,186,000
Net cash used by investing activities	(<u>8,564,000</u>)	(<u>20,905,000</u>)

COMBINED STATEMENTS OF CASH FLOWS, Continued for the years ended June 30, 2022 and 2021

	<u>2022</u>	<u>2021</u>
Cash flows from financing activities: Issuance of long-term debt Payments on debt Payments on finance lease liabilities Payments of debt issuance costs	\$ 49,552,000 (23,881,000) (953,000) (604,000)	\$ 2,123,000 (1,067,000) (580,000)
Net cash provided by financing activities	<u>24,114,000</u>	476,000
Increase (decrease) in cash and cash equivalents	23,845,000	(846,000)
Cash and cash equivalents, beginning of year	<u>19,954,000</u>	20,800,000
Cash and cash equivalents, end of year	\$ <u>43,799,000</u>	\$ <u>19,954,000</u>
Reconciliation of cash and cash equivalents to the combined balance sheets:		
Cash in current assets Cash and cash equivalents in assets limited as to use	\$ 12,160,000 <u>31,639,000</u>	\$ 14,574,000 <u>5,380,000</u>
Total	\$ <u>43,799,000</u>	\$ <u>19,954,000</u>
Interest paid during the year	\$ <u>1,153,000</u>	\$ <u>917,000 </u>
Assets acquired through leases	\$ <u>237,000</u>	\$ <u>3,789,000</u>

Supplemental disclosures of cash flow information:

- Property and equipment and intangible assets in accounts payable as of June 30, 2022 and 2021 was approximately \$600,000 and \$1,624,000, respectively.
- The Corporation received PPP loan forgiveness of approximately \$9,265,000 from SBA in 2022. See Note 1 for additional information.

See accompanying notes to the combined financial statements.

NOTES TO COMBINED FINANCIAL STATEMENTS June 30, 2022 and 2021

1. Description of Organization and Summary of Significant Accounting Policies

Organization

The Hospital Authority of Crisp County (Authority) reorganized and established Crisp Regional Health Services, Inc. (Corporation) as the controlling company of Crisp Regional Hospital, Inc. (Hospital), Crisp Regional Development Foundation, Inc., and Crisp Medical Services, Inc.

Crisp Regional Hospital, Inc. and Crisp Regional Development Foundation, Inc. are not-for-profit corporations. Crisp Regional Hospital, Inc. operates Crisp Regional Hospital (acute care hospital), Crisp Regional Nursing and Rehabilitation Center (CRNRC) (skilled nursing facility), CareSouth of Crisp Regional Hospital (home health agency), Blackshear Retirement Villa (a retirement facility), and Cordele Health and Rehabilitation Center, Inc. (COR) (skilled nursing facility). In addition, Crisp Regional Hospital, Inc. operates various health clinics and physician practices.

Crisp Medical Services, Inc. is a dormant for-profit corporation organized to conduct taxable activities.

On June 1, 2022, Crisp Regional Hospital Portfolio Insurance Company (CRHPIC) was incorporated as an exempted company under the Companies Law of the Cayman Islands. CRHPIC is a wholly-owned subsidiary of the Corporation established to provide general liability, professional liability, and employee benefit plan administration liability insurance coverage to the Corporation (see Note 12).

All material interfacility transactions have been eliminated.

Reorganization

The Authority implemented a reorganization plan whereby all the assets, management and governance of the Hospital were transferred to Crisp Regional Hospital, Inc., a not-for-profit corporation, qualified as an organization described in Section 501(c)(3) of the Internal Revenue Code. The transfer was made pursuant to a Lease and Transfer Agreement between the Hospital Authority and the Corporation. The lease was subsequently amended and became effective July 1, 1996, with a term of forty years. On September 21, 2021, the lease was amended in conjunction with the issuance of the Series 2021 Revenue Certificates (see Note 8) and extended the lease term for an additional forty years to expire in September 2061.

Use of Estimates

The preparation of the combined financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the combined financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

1. <u>Description of Organization and Summary of Significant Accounting Policies, Continued</u>

Cash and Cash Equivalents

Cash and cash equivalents include certain investments in highly liquid debt instruments with original maturities of three months or less. These amounts are reported at cost plus accrued interest.

Investments

Investments in equity securities with readily determinable fair values and all investments in debt securities, which are classified as trading securities, are measured at fair value on the combined balance sheet. Investments without a readily determinable fair value are measured at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Investment income or loss (including realized and unrealized gains and losses on investments, interest and dividends) is included in excess revenues unless the income or loss is restricted by donor or law.

Assets Limited as to Use

Assets limited as to use primarily include assets held by trustees under indenture agreements, assets restricted for collateral on loan agreements, and designated assets set aside by the Board of Directors for future capital improvements, over which the Board retains control and may at its discretion subsequently use for other purposes. Amounts required to meet current liabilities of the Corporation have been reclassified on the combined balance sheet at June 30, 2022 and 2021.

Property and Equipment

Property and equipment acquisitions are recorded at cost. Depreciation is provided over the estimated useful life of each depreciable asset and is computed using the straight-line method. Finance lease assets are amortized on the straight-line method over the shorter period of the lease term or the estimated useful life of the asset. Such amortization is included in depreciation and amortization in the combined financial statements.

Gifts of long-lived assets such as land, buildings or equipment are reported as increases in net assets without donor restrictions, and are excluded from excess revenues, unless explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as increases in net assets with donor restrictions. Absent explicit donor stipulations about how long those long-lived assets must be maintained, expirations of donor restrictions are reported when the donated or acquired long-lived assets are placed in service.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

1. <u>Description of Organization and Summary of Significant Accounting Policies, Continued</u>

Impairment of Long-Lived Assets

The Corporation evaluates on an ongoing basis the recoverability of its assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is required to be recognized if the carrying value of the asset exceeds the undiscounted future net cash flows associated with that asset. The impairment loss to be recognized is the amount by which the carrying value of the long-lived asset exceeds the asset's fair value. In most instances, the fair value is determined by discounted estimated future cash flows using an appropriate interest rate. The Corporation has not recorded any impairment charges in the accompanying combined statements of operations and changes in net assets for the years ended June 30, 2022 and 2021.

Goodwill and Intangible Assets

Goodwill and intangible assets with indefinite lives are tested for impairment annually and more frequently in the event of an impairment indicator. Intangible assets with definite lives are amortized over their respective estimated useful lives, and reviewed whenever events or circumstances indicate impairment may exist.

The Corporation assesses qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events or circumstances, the Corporation determines it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is required. If the two-step impairment test is determined to be necessary, and in step two the carrying value of a reporting unit's goodwill exceeds its implied fair value, an impairment loss equal to the difference will be recorded.

The Corporation considers certain factors such as whether macroeconomic conditions, industry considerations, cost factors, and the sequence of events during the COVID-19 pandemic constituted a triggering event. The Corporation's evaluation determined it is not more likely than not that the reporting unit's fair value is less than its carrying value.

As of June 30, 2022 and 2021, the Corporation had goodwill and intangible assets of approximately \$9,580,000 and \$10,658,000, respectively. The Corporation has elected June 30th as its annual impairment assessment date. The Corporation completed its annual impairment assessment and concluded that no goodwill or indefinite lived intangible asset impairment charge was required.

Costs of Borrowing

Interest cost incurred on borrowed funds during the period of construction of capital assets is capitalized as a component of the cost of acquiring those assets.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

1. <u>Description of Organization and Summary of Significant Accounting Policies, Continued</u>

Debt Issuance Costs

Debt issuance costs are amortized over the period the obligation is outstanding using the straight-line method which approximates the effective interest method over the life of the related debt. Debt issuance costs related to a recognized debt liability are presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability.

Net Assets

Net assets, revenues, gains, and losses are classified based on the existence or absence of donor imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

Net assets without donor restrictions - net assets available for use in general operations and not subject to donor imposed restrictions. The Board of Directors has discretionary control over these resources. Designated amounts represent those net assets that the Board has set aside for a particular purpose. All revenue not restricted by donors and donor restricted contributions whose restrictions are met in the same period in which they are received are accounted for in net assets without donor restrictions.

Net assets with donor restrictions - net assets subject to donor imposed restrictions. Some donor imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. All revenues restricted by donors as to either timing or purpose of the related expenditures or required to be maintained in perpetuity as a source of investment income are accounted for in net assets with donor restrictions. When a donor restriction expires, that is when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions.

Excess Revenues

The statement of operations includes excess revenues. Changes in net assets without donor restrictions which are excluded from excess revenues, consistent with industry practice, include contributions of long-lived assets (including assets acquired using contributions which by donor restriction were to be used for the purposes of acquiring such assets).

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

1. <u>Description of Organization and Summary of Significant Accounting Policies, Continued</u>

Net Patient Service Revenue

The Corporation has agreements with third-party payors that provide for payments to the Corporation at amounts different from its established rates. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges, and per diem payments. Net patient service revenue is reported at the amount that reflects the consideration to which the Corporation expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors, and others and includes variable consideration for retroactive revenue adjustments under reimbursement arrangements with third-party payors. Retroactive adjustments are included in the determination of the estimated transaction price and adjusted in future periods as settlements are determined.

Indigent and Charity Care

The Corporation provides care to patients who meet certain criteria under its Financial Assistance Policy without charge or at amounts less than its established rates. Because the Corporation does not pursue collection of amounts determined to qualify as indigent and charity care, they are not reported as revenue.

Estimated Malpractice and Other Self-Insurance Costs

The provisions for estimated medical malpractice claims and other claims under self-insurance plans include estimates of the ultimate costs for both reported claims and claims incurred but not reported (see Notes 12 and 13).

Income Taxes

Crisp Regional Health Services, Inc., Crisp Regional Hospital, Inc. and Crisp Regional Development Foundation, Inc. are not-for-profit corporations that have been recognized as tax-exempt pursuant to Section 501(c)(3) of the Internal Revenue Code. Crisp Regional Hospital Portfolio Insurance Company is exempted from all local income, profit, or capital gains taxes until July 28, 2042 under the Cayman Islands Tax Concessions Law.

The Corporations apply accounting policies that prescribe when to recognize and how to measure the financial statement effects of income tax positions taken or expected to be taken on its income tax returns. These rules require management to evaluate the likelihood that, upon examination by the relevant taxing jurisdictions, those income tax positions would be sustained. Based on that evaluation, they only recognize the maximum benefit of each income tax position that is more than 50% likely of being sustained. To the extent that all or a portion of the benefits of an income tax position are not recognized, a liability would be recognized for the unrecognized benefits, along with any interest and penalties that would result from disallowance of the position. Should any such penalties and interest be incurred, they would be recognized as operating expenses.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

1. <u>Description of Organization and Summary of Significant Accounting Policies, Continued</u>

Income Taxes, Continued

Based on the results of management's evaluation, no liability is recognized in the accompanying combined balance sheet for unrecognized income tax positions. Further, no interest or penalties have been accrued or charged to expense as of June 30, 2022 and 2021 or for the years then ended. The Corporations' tax returns are subject to possible examination by the taxing authorities. For federal income tax purposes, the tax returns essentially remain open for possible examination for a period of three years after the respective filing deadlines of those returns.

Fair Value Measurements

FASB ASC 820, *Fair Value Measurements and Disclosures* defines fair value as the amount that would be received for an asset or paid to transfer a liability (i.e., an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820 describes the following three levels of inputs that may be used:

- *Level 1:* Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
- *Level 2:* Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.
- *Level 3:* Unobservable inputs when there is little or no market data available, thereby requiring an entity to develop its own assumptions. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Paycheck Protection Program

In May 2021, the Corporation received loan proceeds in the amount of \$9,265,000 under the Paycheck Protection Program (PPP). The PPP, established as part of the Coronavirus Aid Relief, and Economic Security Act (CARES Act), provides for loans to qualifying businesses for amounts up to 2.5 times the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after the covered period as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the covered period. The unforgiven portion of the PPP loan is payable over five years at an interest rate of 1 percent, with a deferral of

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

1. <u>Description of Organization and Summary of Significant Accounting Policies, Continued</u>

Paycheck Protection Program, Continued

payments for the first ten months after the covered period. PPP loans greater than \$2 million are subject to review by the Small Business Administration (SBA). The Corporation initially accounted for the PPP loan as debt addressed in FASB ASC 470. As the program evolved and more information became available, the Corporation determined it was preferable to change its method of accounting and elected to analogize to FASB ASC 958-605. Therefore, the Corporation has retrospectively applied the change in accounting principle to account for the PPP loan as a governmental grant in which the PPP conditional advance payments are reported as a refundable advance until conditions are substantially met or explicitly waived. The retrospective application had no impact on net assets or excess revenues in the accompanying combined financial statements. The Corporation believes its use of the proceeds is consistent with the PPP and during fiscal year 2022 applied for and received full forgiveness of the PPP loan from the SBA. The Corporation recognizes forgiveness as qualifying expenditures are incurred and other limitation conditions are substantially met and recognized \$9,265,000 in fiscal year 2022.

Subsequent Events

In preparing these combined financial statements, the Corporation has evaluated events and transactions for potential recognition or disclosure through October 25, 2022, the date the combined financial statements were issued.

2. <u>Net Patient Service Revenue</u>

Net patient service revenue is reported at the amount that reflects the consideration to which the Corporation expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including health insurers and government programs), and others and includes variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Corporation bills the patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the Corporation. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. The Corporation believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patient services. The Corporation measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. These services are considered to be a single performance obligation and have a duration of less than one year. Revenue for performance obligations satisfied at a point in time is recognized when services are provided and the Corporation does not believe it is required to provide additional services to the patient.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

ne 00, 2022 and 202

2. Net Patient Service Revenue, Continued

Because all of its performance obligations relate to contracts with a duration of less than one year, the Corporation has elected to apply the optional exemption provided in FASB ASC 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The Corporation is utilizing the portfolio approach practical expedient in ASC 606 for contracts related to net patient service revenue. The Corporation accounts for the contracts within each portfolio as a collective group, rather than individual contracts, based on the payment pattern expected in each portfolio category and the similar nature and characteristics of the patients within each portfolio. As a result, the Corporation has concluded that revenue for a given portfolio would not be materially different than if accounting for revenue on a contract by contract basis.

The Corporation has arrangements with third-party payors that provide for payments to the Corporation at amounts different from its established rates. For uninsured patients that do not qualify for indigent and charity care, the Corporation recognizes revenue on the basis of its standard rates, subject to certain discounts and implicit price concessions as determined by the Corporation. The Corporation determines the transaction price based on standard charges for services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Corporation's policy, and implicit price concessions provided to uninsured patients. Implicit price concessions represent the difference between amounts billed and the estimated consideration the Corporation expects to receive from patients, which are determined based on historical collection experience, current market conditions, and other factors. The Corporation determines its estimates of contractual adjustments and discounts based on contractual agreements, discount policies, and historical experience.

Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows:

<u>Medicare</u>

Inpatient acute care and outpatient services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors.

Nursing Home services rendered to Medicare program beneficiaries are paid based on a patient-driven payment methodology.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

2. <u>Net Patient Service Revenue, Continued</u>

• Medicare, Continued

The Corporation is reimbursed for cost reimbursable items at a tentative rate with final settlement determined after submission of annual cost reports by the Corporation and audits thereof by the Medicare Administrative Contractor (MAC). The Corporation's classification of patients under the Medicare program and the appropriateness of their admission are subject to an independent review by a peer review organization under contract with the Corporation. The Corporation's Medicare cost reports have been audited by the MAC through June 30, 2018.

• <u>Medicaid</u>

Inpatient acute care services rendered to Medicaid program beneficiaries are paid at a prospectively determined rate per discharge. These rates vary according to a patient classification system that is based on clinical, diagnostic and other factors. Outpatient services rendered to Medicaid program beneficiaries are reimbursed under a reduced cost reimbursement methodology.

The Corporation is reimbursed at a tentative rate with final settlement determined after submission of annual cost reports by the Corporation and audits thereof by the Medicaid fiscal intermediary. The Corporation's Medicaid cost reports have been audited by the Medicaid fiscal intermediary through June 30, 2019.

The Corporation has also entered into contracts with certain managed care organizations to receive reimbursement for providing services to selected enrolled Medicaid beneficiaries. Payment arrangements with these managed care organizations consist primarily of prospectively determined rates per discharge, discounts from established charges, or prospectively determined per diems.

Nursing Home services are reimbursed by the Medicaid program based on a prospectively determined per diem. The per diem is determined by the facility's historical allowable operating costs adjusted for certain incentives and inflation factors.

The Hospital participates in the Georgia Indigent Care Trust Fund (ICTF) Program. The Hospital receives ICTF payments for treating a disproportionate number of Medicaid and uninsured patients. ICTF payments are based on the Hospital's estimated uncompensated cost of services to Medicaid and uninsured patients. The amount of ICTF payments recognized in net patient service revenue was approximately \$1,586,000 and \$1,287,000 for the years ended June 30, 2022 and 2021, respectively.

The Medicare, Medicaid and SCHIP Benefits Improvement and Protection Act of 2000 (BIPA) provides for payment adjustments to certain facilities based on the Medicaid Upper Payment Limit (UPL). The UPL payment adjustments are based on a measure of the

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

2. <u>Net Patient Service Revenue, Continued</u>

• Medicaid, Continued

difference between Medicaid payments and the amount that could be paid based on Medicare payment principles. The Hospital and Nursing Homes participate in this program. The net amount of UPL payment adjustments recognized in net patient service revenue was approximately \$4,228,000 and \$3,275,000 for the years ended June 30, 2022 and 2021, respectively.

During 2022, Medicaid implemented the Medicaid CMOs Direct Payment Program (DPP). Under the DPP, eligible hospitals will receive increased Medicaid funding via an annual lump sum direct payment. The direct payment will be based on the difference between Medicare reimbursement and Medicaid payments using UPL calculations. The direct payment is made to the CMOs and the CMOs are required to transfer the payment to the hospital. The net amount of DPP payment adjustments recognized in net patient service revenue was approximately \$425,000 during 2022.

During 2022, Medicaid implemented the Supplemental Quality Incentive (SQI) payment program for nursing homes that demonstrate improvement in one of four quality metrics. CRNRC demonstrated improvement in two of the four quality metrics and recognized SQI payments of approximately \$355,000 during 2022, and COR demonstrated improvement in three of the four quality metrics and recognized SQI payments of approximately \$812,000 during 2022. These payments are reported in net patient service revenue on the combined statements of operations and changes in net assets.

During 2010, the state of Georgia enacted legislation known as the Provider Payment Agreement Act (Act) whereby hospitals in the state of Georgia are assessed a "provider payment" in the amount of 1.45% of their net patient revenue. The Act became effective July 1, 2010, the beginning of state fiscal year 2011. The provider payments are due on a quarterly basis to the Department of Community Health. The payments are to be used for the sole purpose of obtaining federal financial participation for medical assistance payments to providers on behalf of Medicaid recipients. The provider payment will result in an increase in hospital payments on Medicaid services of approximately 11.88%. Approximately \$829,000 and \$801,000 relating to the Act is included in administrative services in the accompanying combined statements of operations and changes in net assets for the years ended June 30, 2022 and 2021, respectively.

Other Arrangements

The Corporation has also entered into payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. The basis for payment to the Corporation under these agreements includes prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

2. <u>Net Patient Service Revenue, Continued</u>

Uninsured Patients

The Corporation has a Financial Assistance Policy (FAP) in accordance with Internal Revenue Code Section 501(r). Based on the FAP, following a determination of financial assistance eligibility, an individual will not be charged more than the Amounts Generally Billed (AGB) for emergency or other medical care provided to individuals with insurance covering that care. AGB is calculated by reviewing claims that have been paid in full (including deductibles and coinsurance paid by the patient) to the Corporation for medically necessary care by Medicare and private health insurers during a 12-month look-back period.

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Corporation's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon the Corporation. In addition, the contracts the Corporation has with commercial payors also provide for retroactive audit and review of claims.

Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Corporation's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. Adjustments arising from a change in the transaction price, were not significant in 2022 or 2021.

Generally patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The Corporation also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Corporation estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

2. Net Patient Service Revenue, Continued

Adjustments arising from a change in the transaction price were not significant for the years ending June 30, 2022 and 2021. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay are recorded as bad debt expense. Bad debt expense for the years ended June 30, 2022 and 2021 was not significant.

Consistent with the Corporation's mission, care is provided to patients regardless of their ability to pay. Therefore, the Corporation has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances (for example, copays and deductibles).

Patients who meet the Corporation's criteria for indigent and charity care are provided care without charge or at amounts less than established rates. Such amounts determined to qualify as indigent and charity care are not reported as revenue.

Net patient service revenue by major payor source for the years ended June 30, 2022 and 2021 is as follows:

	<u>2022</u>	<u>2021</u>
Medicare	\$ 43,301,000	\$ 48,570,000
Medicaid	26,112,000	16,648,000
Other third-party payors	43,759,000	40,272,000
Self-pay	<u>806,000</u>	<u>812,000</u>
Total	\$ <u>113,978,000</u>	\$ <u>106,302,000</u>

Net patient service revenue by facility, line of business, and timing of revenue recognition for the years ended June 30, 2022 and 2021 are as follows:

	<u>2022</u>	<u>2021</u>
Hospital Skilled nursing facility - COR Skilled nursing facility - CRNRC Home health agency Retirement facility	\$ 98,468,000 6,953,000 6,465,000 1,762,000 <u>330,000</u>	\$ 90,868,000 6,356,000 6,649,000 2,166,000 <u>263,000</u>
Timing of revenue recognition: Services transferred over time	\$ <u>113,978,000</u>	\$ <u>106,302,000</u>

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

2. <u>Net Patient Service Revenue, Continued</u>

Hospital net patient service revenue includes a variety of services mainly covering inpatient acute care services requiring overnight stays, outpatient procedures that require anesthesia or use of the Corporation's diagnostic and surgical equipment, and emergency care services. Performance obligations for the hospital, skilled nursing facilities, home health agency, and the retirement facility patient services are satisfied over time as the patient simultaneously receives and consumes the benefits the Corporation performs. Requirements to recognize revenue for hospital inpatient services are generally satisfied over periods that average approximately four days and for outpatient services are generally satisfied over a period of less than one day. Retail pharmacy, cafeteria, and gift shop revenue, recorded in other revenue on the combined statements of operations and changes in net assets, performance obligations are satisfied at a point in time when the goods are provided.

The Corporation has elected the practical expedient allowed under FASB ASC 606-10-32-18 and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Corporation's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, the Corporation does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract.

The Corporation has applied the practical expedient provided by FASB ASC 340-40-25-4 and all incremental customer contract acquisition costs are expensed as they are incurred as the amortization period of the asset that the Corporation otherwise would have recognized is one year or less in duration.

3. Uncompensated Services

The Corporation was compensated for services at amounts less than its established rates. Charges for uncompensated services for 2022 and 2021 were approximately \$213,937,000 and \$222,079,000, respectively.

Uncompensated care includes indigent and charity care services of approximately \$4,039,000 and \$2,616,000 in 2022 and 2021, respectively. The cost of indigent and charity care services provided during 2022 and 2021 was approximately \$1,415,000 and \$857,000, respectively computed by applying a total cost factor to the charges foregone.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

3. <u>Uncompensated Services, Continued</u>

The following is a summary of uncompensated services and a reconciliation of gross patient charges to net patient service revenue for 2022 and 2021.

	<u>2022</u>	<u>2021</u>
Gross patient charges	\$ <u>327,915,000</u>	\$ <u>328,381,000</u>
Uncompensated services:		
Indigent and charity care	4,039,000	2,616,000
Medicare	116,639,000	116,963,000
Medicaid	26,029,000	33,354,000
Other third-party payors	37,508,000	37,488,000
Price concessions	29,722,000	31,658,000
Total uncompensated care	<u>213,937,000</u>	<u>222,079,000</u>
Net patient service revenue	\$ <u>113,978,000</u>	\$ <u>106,302,000</u>

4. <u>Concentrations of Credit Risk</u>

The Corporation grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The mix of receivables from patients and third-party payors at June 30, 2022 and 2021, was as follows:

	<u>2022</u>	<u>2021</u>
Medicare Medicaid Other third-party payors Patients	31% 25% 39% <u>5</u> %	36% 18% 38% <u>8</u> %
Total	<u>100</u> %	<u>100</u> %

At June 30, 2022, the Corporation had deposits at major financial institutions which exceeded the \$250,000 Federal Deposit Insurance Corporation limit. Management believes the credit risks related to these deposits is minimal.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

5. <u>Investments</u>

The composition of assets limited as to use at June 30, 2022 and 2021 is set forth in the following table. Investments other than cash and cash equivalents and certificate of deposit are stated at fair value.

Assets Limited as to Use

	<u>2022</u>	<u>2021</u>
Internally designated for capital improvements:		
Cash and cash equivalents	\$ 4,148,000	\$ 4,035,000
Government and agency securities	10,768,000	11,949,000
Mutual funds - income and growth	5,485,000	427,000
U.S. corporate bonds	9,142,000	9,200,000
Exchange traded funds	5,008,000	11,675,000
Asset and mortgage backed securities	1,391,000	1,939,000
Common stock	19,577,000	23,110,000
Real estate investment trusts	932,000	807,000
Total	56,451,000	63,142,000
Held by trustee under indenture: Cash and cash equivalents	27,491,000	1,345,000
Externally restricted for collateral: Certificate of deposit	1,002,000	1,001,000
Total assets limited as to use	\$ <u>84,944,000</u>	\$ <u>65,488,000</u>

The Corporation's certificate of deposit is reported at cost plus accrued interest.

The Corporation's investments are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the accompanying combined financial statements.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

5. Investments, Continued

Fair values of assets measured on a recurring basis at June 30, 2022 and 2021 are as follows:

<u>June 30, 2022</u>	<u>Fair Value</u>	Fair Value Measu Quoted Prices in Active Markets For Identical Assets (Level 1)	rements at Repo Significant Other Observable Inputs (<u>Level 2</u>)	orting Date Using Significant Unobservable Inputs (<u>Level 3</u>)
Assots:				
Assets: Government and				
agency securities Mutual funds - income	\$ 10,768,000	\$ 10,768,000	\$ -	\$ -
and growth	5,485,000	5,485,000	-	-
U.S. corporate bonds	9,142,000	9,142,000	-	-
Exchange traded funds Asset and mortgage	5,008,000	5,008,000	-	-
backed securities	1,391,000	1,391,000	-	-
Common stock	19,577,000	19,577,000	-	-
Real estate investment				
trusts	932,000	932,000		
Total assets	\$ <u>52,303,000</u>	\$ <u>52,303,000</u>	\$	\$
<u>June 30, 2021</u>				
Assets:				
Government and				
agency securities	\$ 11,949,000	\$ 11,949,000	\$-	\$ -
Mutual funds - income				
and growth	427,000	427,000	-	-
U.S. corporate bonds	9,200,000	9,200,000	-	-
Exchange traded funds Asset and mortgage	11,675,000	11,675,000	-	-
backed securities	1,939,000	1,939,000	_	_
Common stock	23,110,000	23,110,000	-	-
Real estate investment	, ,	,,		
trusts	807,000	807,000		
Total assets	\$ <u>59,107,000</u>	\$ <u>59,107,000</u>	\$	\$

Financial assets valued using Level 1 inputs are based on unadjusted quoted market prices within active markets. Valuation techniques utilized to determine fair value are consistently applied.

All assets have been valued using a market approach.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

6. Property and Equipment

A summary of property and equipment at June 30, 2022 and 2021 follows:

	2022	<u>2021</u>
Land	\$ 3,678,000	\$ 3,677,000
Land improvements	1,375,000	1,342,000
Buildings and improvements	52,263,000	50,995,000
Fixed equipment	15,641,000	14,417,000
Movable equipment	42,631,000	38,134,000
Finance lease right-of-use assets	3,554,000	3,367,000
	119,142,000	111,932,000
Less accumulated depreciation	(<u>75,232,000</u>)	(<u>70,120,000</u>)
	43,910,000	41,812,000
Construction in progress	1,000,000	1,420,000
Property and equipment, net	\$ <u>44,910,000</u>	\$ <u>43,232,000</u>

Depreciation expense for the years ended June 30, 2022 and 2021 amounted to approximately \$4,366,000 and \$3,987,000, respectively.

Amortization expense on finance lease right-of-use assets for the years ended June 30, 2022 and 2021 amounted to approximately \$897,000 and \$626,000, respectively.

7. Notes Receivable

Notes receivable consist primarily of loans to physicians and medical school students for tuition and related educational expenses, which are secured by promissory notes. In general, the receivables are being forgiven over a period of time in which the physician practices medicine in Cordele, Georgia. If the physician discontinues medical practice in Cordele or the student is no longer enrolled in medical school, the outstanding principal and accrued interest becomes due immediately. The amounts forgiven and charged to expense during 2022 and 2021 were approximately \$198,000 and \$226,000, respectively.

Notes receivable also consist of educational loans to employees. In general, the educational loans are forgiven over a period of time in which the employee works for the Corporation.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

8. Long-Term Debt

A summary of long-term debt at June 30, 2022 and 2021 follows:

	2022	<u>2021</u>
2013 Revenue Certificates, with principal payments due on July 1 st each year from 2029 through 2043, varying rates of interest from 3.50% to 4.15%, secured by a pledge of the Authority's gross receipts. Net of unamortized issue costs of \$-0- and \$619,000 at June 30, 2022 and 2021, respectively.	\$-	\$ 15,881,000
2015 Revenue Certificates, with principal payments due on July 1 st each year from 2017 through 2028, interest at 2.47%, secured by a pledge of the Authority's gross receipts. Net of unamortized issue costs of \$-0- and \$104,000 at June 30, 2022 and 2021, respectively.	_	7,026,000
2021 Revenue Certificates, with principal payments due on July 1 st each year from 2023 through 2052, varying rates of interest from 3.00% to 5.00%, secured by a pledge of the Authority's gross receipts. Net of unamortized issue costs of \$590,000 and unamortized premium of \$7,984,000 at June 30, 2022.	48,779,000	_
Note payable to Crisp County Power Commission with monthly installments of \$8,000 through July 2030. Incurring interest at 0.00%. Secured by a certificate of deposit.	825,000	925,000
Note payable to a bank with monthly principal and interest payments of \$15,000 through August 2027. Incurring interest at 2.90%. Secured by equipment.	850,000	1,001,000
Finance lease liabilities (Note 9)	2,020,000	2,787,000
Total long-term debt	52,474,000	27,620,000
Less current installments of long-term debt	1,764,000	1,994,000
Total long-term debt excluding current installments	\$ <u>50,710,000</u>	\$ <u>25,626,000</u>

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

8. Long-Term Debt, Continued

The Series 2008A, 2008B, 2013, 2015, and 2021 Certificates were issued pursuant to trust indentures between the Authority, the Corporation, and U.S. Bank National Association, as Trustee.

On May 1, 2008, the Authority issued \$10,000,000 of the Hospital Authority of Crisp County, Georgia Revenue Anticipation Certificates (Crisp Regional Hospital Project) Series 2008A for the purpose of (i) refunding the Authority's outstanding revenue notes (Crisp Regional Hospital Project), Series 2007, (ii) financing, in whole or in part, the cost of the acquisition, construction, and equipping of capital improvements (ICU addition) to the healthcare facilities of the Authority located in Crisp County, Georgia (Project), (iii) paying the premium for a municipal bond insurance policy relating to the Series 2008A Certificates, and (iv) paying all or a portion of the costs of issuing the Series 2008A Certificates.

On May 28, 2008, the Authority issued \$3,000,000 of the Hospital Authority of Crisp County, Georgia Revenue Anticipation Certificates (Crisp Regional Hospital Project), Series 2008B for the purpose of (i) financing in whole or in part, the costs of the acquisition, construction and equipping of capital improvements (ICU addition) to the healthcare facilities of the Authority located in Crisp County, Georgia (Project), (ii) paying the premium for a municipal bond insurance policy relating to the Series 2008B Certificates, and (iii) paying a portion of the costs of issuing the Series 2008B Certificates.

On June 1, 2013, the Authority issued \$16,500,000 of the Hospital Authority of Crisp County, Georgia Revenue Anticipation Certificates (Crisp Regional Hospital Project), Series 2013 for the purpose of (i) expansions and renovations to the emergency department, (ii) acquisition, expansions and renovations to skilled nursing facilities, (iii) acquisition and installation of information technology equipment and software, (iv) routine capital equipment, and (v) acquisition and installation of certain radiology and fluorography equipment.

On April 1, 2015, the Authority issued \$11,185,000 of the Hospital Authority of Crisp County, Georgia Revenue Anticipation Certificates (Crisp Regional Hospital Project), Series 2015 for the purpose of defeasing the Series 2008A Certificates maturing in the years 2016 and after and the Series 2008B Certificates maturing in the years 2017 and after.

On September 1, 2021, the Authority issued \$41,385,000 of the Hospital Authority of Crisp County, Georgia Revenue Anticipation Certificates (Crisp Regional Hospital Project), Series 2021 for the purpose of (i) financing or refunding a portion of the cost of acquisition, construction, installation and equipping of hospital and related facilities of the Corporation, (ii) refunding the Series 2013 and 2015 Certificates, and (iii) paying all or a portion of the costs of issuance of the 2021 Certificates. As a result of the refunding of the Series 2013 and 2015 Certificates, the Corporation recognized a loss on refunding of approximately \$778,000. The loss mainly represents the write-off of the unamortized issuance costs of the Series 2013 and 2015 Certificates and is reported in other income (loss) in the combined statements of

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

8. Long-Term Debt, Continued

operations and changes in net assets. The refunding of the Series 2013 and 2015 Certificates reduced the Corporation's debt service requirements on those funds by approximately \$4,433,000, which resulted in an economic gain (difference between the present value of the debt service payments on the old and new debt) of approximately \$3,546,000

In accordance with the Trust Indenture with U. S. Bank National Association, the Corporation is required to establish sinking funds to accumulate specific principal and interest payments due on January 1 and July 1 each year. In addition, the Corporation is required to meet certain debt service restrictions. As of June 30, 2022, management believes the requirements of the Trust Indenture were met.

Scheduled principal repayments on long-term debt (excluding finance lease liabilities) are as follows:

Year	Long-Term Debt
2023	\$ 815,000
2024	994,000
2025	1,029,000
2026	1,064,000
2027	1,099,000
Thereafter	<u>38,059,000</u>
	43,060,000
Less: debt issue costs	590,000
Add: unamortized premium	7,984,000
Total	\$ <u>50,454,000</u>

9. <u>Leases</u>

The Corporation has operating and finance leases for buildings and equipment. The Corporation determines if an arrangement is a lease at the inception of a contract. Leases with an initial term of twelve months or less are not recorded on the combined balance sheets. The Corporation has lease agreements which require payments for lease and nonlease components and has elected to account for these as a single lease component.

Right-of-use assets represent the Corporation's right to use an underlying asset during the lease term, and lease liabilities represent the Corporation's obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date, based on the net present value of fixed lease payments over the lease term. The Corporation has entered into lease arrangements that contain options to extend or terminate the lease in future periods. These options are included in the lease term used to compute the lease liabilities as presented on the combined balance sheets when it is reasonably certain the option will be exercised.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

9. Leases, Continued

As most of the Corporation's operating leases do not provide an implicit rate, the Corporation uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Corporation considers recent debt issuances, as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates. Finance lease agreements generally include an interest rate that is used to determine the present value of future lease payments. Operating fixed lease expense and finance lease amortization expense are recognized on a straight-line basis over the lease term. Variable lease costs consist primarily of common area maintenance and are not significant to total lease expense.

Operating and finance lease right-of-use assets and lease liabilities as of June 30, 2022 and 2021 were as follows:

	<u>2022</u>	<u>2021</u>
Operating leases: Right-of-use assets: Operating lease right-of-use assets	\$ <u> 88,000</u>	\$ <u>198,000</u>
Lease liabilities: Current portion Long-term	\$ 9,000 	\$ 185,000 <u> 1,000</u>
Total operating lease liabilities	\$ <u> 9,000</u>	\$ <u>186,000</u>
Finance leases: Right-of-use assets: Property and equipment, net	\$ <u>2,028,000</u>	\$
Lease liabilities: Current portion Long-term	\$ 675,000 <u>1,345,000</u>	\$ 839,000 <u>1,948,000</u>
Total finance lease liabilities	\$ <u>2,020,000</u>	\$ <u>2,787,000</u>

Operating expenses for the leasing activity of the Corporation as lessee for the years ended June 30, 2022 and 2021 are as follows:

Lease Type	<u>2022</u>	<u>2021</u>
Operating lease cost Finance lease interest Finance lease amortization	\$ 173,000 57,000 <u>897,000</u>	\$ 214,000 50,000 626,000
Total lease cost	\$ <u>1,127,000</u>	\$ 890,000

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

9. Leases, Continued

Cash paid for amounts included in the measurement of lease liabilities for the years ended June 30, 2022 and 2021 is as follows:

		<u>2022</u>	4	2021
Operating cash flows from operating leases Operating cash flows from finance leases Financing cash flows from finance leases	\$	228,000 57,000 953,000		36,000 50,000 <u>80,000</u>
Total	\$ <u>1</u>	<u>,238,000</u>	\$ <u>8</u>	<u>66,000</u>

The aggregate future lease payments for operating and finance leases as of June 30, 2022 were as follows:

Year Ending June 30	Finance	<u>Operating</u>
2023 2024 2025 2026	\$ 715,000 615,000 546,000 224,000	\$ 9,000 - - -
Total undiscounted cash flows	2,100,000	9,000
Less: present value discount	(<u>80,000</u>)	
Total lease liabilities	\$ <u>2,020,000</u>	\$ <u>9,000</u>

Average lease terms and discount rates at June 30, 2022 and 2021 were as follows:

	<u>2022</u>	<u>2021</u>
Weighted-average remaining lease term (years):		
Operating leases	2.07	1.04
Finance leases	3.36	4.09
Weighted-average discount rate:		
Operating leases	3.00%	3.00%
Finance leases	2.43%	2.46%

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

10. <u>Goodwill and Intangibles, Net</u>

A summary of goodwill and intangibles at June 30, 2022 and 2021 follows:

	<u>2022</u>	<u>2021</u>
Certificate of Need - Cordele Health and Rehabilitation Center, Inc. Information system intangible assets Accumulated amortization Intangible assets, net Goodwill	\$ 1,800,000 8,422,000 (<u>2,389,000</u>) 7,833,000 <u>1,747,000</u>	\$ 1,800,000 8,652,000 (<u>1,541,000</u>) 8,911,000 <u>1,747,000</u>
Total goodwill and intangible assets, net	\$ <u>9,580,000</u>	\$ <u>10,658,000</u>

The Corporation entered into a contract to convert its information systems. The cost associated with the conversion resulted in intangible assets which are being amortized over the information system's estimated useful life.

The goodwill is related to the Hospital's purchase of Cordele Health and Rehabilitation Center, Inc., Crisp Regional Nursing and Rehabilitation Center and various physician practices. Goodwill is evaluated annually for impairment.

The changes in the carrying amount of goodwill for the year ended June 30, 2022 and 2021 are as follows:

	<u>2022</u>	<u>2021</u>
Balance at beginning of the year: Goodwill Accumulated impairment losses	\$ 1,747,000 	\$ 1,747,000
Net beginning goodwill	<u>1,747,000</u>	<u>1,747,000</u>
Goodwill acquired during the year Impairment losses	<u> </u>	-
Balance at end of the year: Goodwill Accumulated impairment losses	1,747,000	1,747,000
Net ending goodwill	\$ <u>1,747,000</u>	\$ <u>1,747,000</u>

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

11. <u>Retirement Plan</u>

The Corporation has a defined contribution plan for all full-time employees. The Hospital funds tax-sheltered annuities for employees under the defined contribution plan. Amounts to be funded are based on an employee's years of employment. Funding ranges from 3% to 5% of an employee's base salary.

Retirement benefits included in the June 30, 2022 and 2021 combined financial statements are approximately \$815,000 and \$1,003,000, respectively.

12. <u>Malpractice Insurance</u>

Through March 31, 2021, the Corporation was covered by a per occurrence general and professional liability insurance policy with a specified deductible per incident and excess coverage on a claims-made basis. Self-insured retention related to this policy was \$250,000 per occurrence. The specific loss, other coverage aggregate and health care professional liability aggregate limits were \$10,000,000. Effective April 1, 2021, the Corporation is covered by an umbrella liability policy for general and professional liability claims in excess of \$1 million, which is the Corporation's self-insured retention per claim. Effective April 15, 2022, the Corporation's self-insured retention for professional liability claims increased to \$2 million, and both professional and general liability claims became subject to an aggregate deductible of \$500,000 per occurrence and \$1 million per policy period. The specific loss and aggregate limits under this policy are \$15,000,000.

As discussed in Note 1, effective June 1, 2022, the Corporation is self-insured for general and professional liability coverage through the Crisp Regional Hospital Portfolio Insurance Company. Liability limits related to the claims-made coverage for professional liability claims are \$2.5 million per claim and \$7 million in aggregate, and general liability claims are \$1.5 million per claim and \$4 million in aggregate. Claims incurred in excess of this coverage are covered by the umbrella policy noted above.

The Corporation uses a third-party administrator to review and analyze incidents that may result in a claim against the Corporation. In conjunction with the third-party administrator, incidents are assigned reserve amounts for the ultimate liability that may result from an asserted claim.

Various claims and assertions have been made against the Corporation in its normal course of providing services. In addition, other claims may be asserted arising from services provided to patients in the past. In the opinion of management, adequate provision has been made for losses which may occur from such asserted and unasserted claims that are not covered by liability insurance.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

13. Employee Health Insurance

The Corporation is under a self-insurance program for the purpose of providing group health insurance for Corporation employees and their covered dependents. This program was created to minimize the total cost of annual medical insurance to the Corporation. The Corporation has purchased stop-loss insurance coverage for claims in excess of \$175,000 for each individual employee.

Under this self-insurance program, the Corporation paid or accrued approximately \$5,605,000 and \$6,787,000 in 2022 and 2021, respectively. These amounts are included in the combined statements of operations and changes in net assets as employee health and welfare expense.

14. Functional Expenses

The Corporation provides general health care services to residents within its geographic location. Expenses related to providing these services are as follows:

		2022	
	Patient Care	General and	
	<u>Services</u>	Administrative	<u>Total</u>
Salaries	\$ 39,606,000	\$ 7,676,000	\$ 47,282,000
Employee benefits	8,981,000	1,741,000	10,722,000
Supplies and drugs	20,602,000	1,760,000	22,362,000
Purchased services and	20,002,000	1,700,000	22,002,000
professional fees	15,890,000	7,234,000	23,124,000
Other	2,248,000	5,720,000	7,968,000
Depreciation and amortization	4,590,000	1,521,000	6,111,000
Interest	1,159,000	384,000	1,543,000
Total	\$ <u>93,076,000</u>	\$ <u>26,036,000</u>	\$ <u>119,112,000</u>
		2021	
	Patient Care	2021 General and	
	Patient Care <u>Services</u>		<u>Total</u>
Salarias	<u>Services</u>	General and <u>Administrative</u>	
Salaries	<u>Services</u> \$ 36,227,000	General and Administrative \$ 6,978,000	\$ 43,205,000
Employee benefits	<u>Services</u> \$ 36,227,000 10,044,000	General and <u>Administrative</u> \$ 6,978,000 1,935,000	\$ 43,205,000 11,979,000
Employee benefits Supplies and drugs	<u>Services</u> \$ 36,227,000	General and Administrative \$ 6,978,000	\$ 43,205,000
Employee benefits Supplies and drugs Purchased services and	<u>Services</u> \$ 36,227,000 10,044,000 19,636,000	General and <u>Administrative</u> \$ 6,978,000 1,935,000 1,550,000	\$ 43,205,000 11,979,000 21,186,000
Employee benefits Supplies and drugs Purchased services and professional fees	<u>Services</u> \$ 36,227,000 10,044,000 19,636,000 11,893,000	General and Administrative \$ 6,978,000 1,935,000 1,550,000 7,796,000	\$ 43,205,000 11,979,000 21,186,000 19,689,000
Employee benefits Supplies and drugs Purchased services and professional fees Other	<u>Services</u> \$ 36,227,000 10,044,000 19,636,000 11,893,000 2,418,000	General and <u>Administrative</u> \$ 6,978,000 1,935,000 1,550,000 7,796,000 5,620,000	\$ 43,205,000 11,979,000 21,186,000 19,689,000 8,038,000
Employee benefits Supplies and drugs Purchased services and professional fees Other Depreciation and amortization	<u>Services</u> \$ 36,227,000 10,044,000 19,636,000 11,893,000 2,418,000 4,092,000	General and Administrative \$ 6,978,000 1,935,000 1,550,000 7,796,000 5,620,000 1,387,000	\$ 43,205,000 11,979,000 21,186,000 19,689,000 8,038,000 5,479,000
Employee benefits Supplies and drugs Purchased services and professional fees Other	<u>Services</u> \$ 36,227,000 10,044,000 19,636,000 11,893,000 2,418,000	General and <u>Administrative</u> \$ 6,978,000 1,935,000 1,550,000 7,796,000 5,620,000	\$ 43,205,000 11,979,000 21,186,000 19,689,000 8,038,000

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

14. Functional Expenses, Continued

The combined financial statements report certain expense categories that are attributable to more than one health care service or support function. Therefore, these expenses require an allocation on a reasonable basis that is consistently applied. Costs not directly attributable to a function, including depreciation and amortization, interest expense, and other occupancy costs, are allocated to a function based on a square footage basis. Benefit expense is allocated consistent with salaries.

15. <u>Contingencies</u>

Regulatory Compliance

The healthcare industry has been subjected to increased scrutiny from governmental agencies at both the federal and state level with respect to compliance with regulations. Areas of noncompliance identified at the national level include Medicare and Medicaid, Internal Revenue Service, and other regulations governing the healthcare industry. In addition, the Reform Legislation includes provisions aimed at reducing fraud, waste, and abuse in the healthcare industry. These provisions allocate significant additional resources to federal enforcement agencies and expand the use of private contractors to recover potentially inappropriate Medicare and Medicaid payments. The Corporation has implemented a compliance plan focusing on such issues. There can be no assurance that the Corporation will not be subjected to future investigations with accompanying monetary damages.

Health Care Reform

There has been increasing pressure on Congress and some state legislatures to control and reduce the cost of healthcare at the national and the state levels. Legislation has been passed that includes cost controls on healthcare providers, insurance market reforms, delivery system reforms and various individual and business mandates among other provisions. The costs of these provisions are and will be funded in part by reductions in payments by government programs, including Medicare and Medicaid. There can be no assurance that these changes will not adversely affect the Corporation.

Litigation

The Corporation has been named as a defendant in certain lawsuits arising in the ordinary course of business. Management does not expect these matters to have a material adverse effect on the financial position and results of operations of the Corporation.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

16. Fair Values of Financial Instruments

The following methods and assumptions were used by the Corporation in estimating the fair value of its financial instruments:

- Cash, cash equivalents, accounts payable, accrued expenses, estimated third-party payor settlements, other liabilities and Medicare advance payments: The carrying amount reported in the balance sheet approximates its fair value due to the short-term nature of these instruments.
- Assets limited as to use: Amounts reported in the balance sheet are at fair value. See Note 5 for fair value measurement disclosures.
- Long-term debt: The fair value of the Corporation's long-term debt is based on the quoted market value for same or similar debt instruments or estimated using discounted cash flow analyses. Based on inputs used in determining the estimated fair value, the Corporation's long-term debt would be classified as Level 2 in the fair value hierarchy.

The following table summarizes the carrying amounts and fair value for long-term debt:

	2022		20)21
	Carrying <u>Amount</u>	Fair Value	Carrying <u>Amount</u>	Fair Value
Long-term debt	\$ <u>51,044,000</u>	\$ <u>42,360,000</u>	\$ <u>25,556,000</u>	\$ <u>25,706,000</u>

17. <u>Rural Hospital Tax Credit Contributions</u>

The State of Georgia (State) passed legislation which will allow individuals or corporations to receive a State tax credit for making a contribution to certain qualified rural hospital organizations during calendar years 2017 through 2024. The Corporation submitted the necessary documentation and was approved by the State to participate in the rural hospital tax credit program for calendar years 2021 and 2022. Contributions received or accrued under the program in 2022 and 2021 approximated \$2,061,000 and \$1,287,000, respectively, and are reported as undesignated gifts and bequests on the combined statements of operations and changes in net assets. The Corporation will have to be approved by the State to participate in the program in each subsequent year.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

18. Liquidity and Availability

As of June 30, 2022 and 2021, the Corporation has working capital of approximately \$25,405,000 and \$27,125,000 and average days (based on normal expenditures) cash on hand of 39 and 48 days, respectively.

Financial assets available for general expenditure within one year of June 30, 2022 and 2021, consist of the following:

	<u>2022</u>	<u>2021</u>
Cash Patient accounts receivable, net Estimated third-party payor settlements Assets limited as to use:	\$ 12,160,000 24,218,000 -	\$ 14,574,000 20,024,000 705,000
Internally designated for capital improvements Other current assets	56,451,000 <u>4,006,000</u>	63,142,000 <u>6,575,000</u>
Total financial assets available	\$ <u>96,835,000</u>	\$ <u>105,020,000</u>

None of the financial assets available are subject to donor or other contractual restrictions that make them unavailable for general expenditure within one year of the balance sheet date. The Corporation estimates that 100% of the Board designated funds for capital improvements are available for general expenditure within one year in the normal course of operations. Accordingly, these assets have been included in the quantitative information above. The Corporation has other assets whose use is limited for debt service, construction projects per debt agreements, and restricted for collateral. These assets whose use is limited are not available for general expenditure within the next year and are not reflected in the amounts above. The Corporation has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due.

19. Coronavirus

As a result of the spread of the COVID-19 coronavirus, economic uncertainties have arisen. The outbreak has put an unprecedented strain on the US healthcare system, disrupted or delayed production and delivery of materials and products in the supply chain, and caused staffing shortages. The extent of the impact of COVID-19 on the Corporation's operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, remedial actions and stimulus measures adopted by local and federal governments, impact on the Corporation's customers, employees and vendors all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact the Corporation's financial position or results of operations is uncertain.

On March 27, 2020, the President signed the Coronavirus Aid, Relief and Economic Security Act (CARES Act). Certain provisions of the CARES Act provide relief funds to hospitals and other healthcare providers. The funding will be used to support healthcare-related expenses or lost revenue attributable to COVID-19. The U.S. Department of Health and Human

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

19. <u>Coronavirus, Continued</u>

Services began distributing funds on April 10, 2020 to eligible providers in an effort to provide relief to both providers in areas heavily impacted by COVID-19 and those providers who are struggling to keep their doors open due to healthy patients delaying care and canceling elective services. The Corporation has received the following CARES Act funding:

- \$30 Billion General Distribution (1st round) On April 10, 2020, HHS distributed \$30 billion to nearly 320,000 Medicare fee-for-service providers based on their portion of 2019 Medicare fee-for-service payments. The Corporation received approximately \$1,415,000 in funding from this distribution.
- \$20 Billion General Distribution (2nd round) On April 24, 2020, HHS distributed \$20 billion to Medicare fee-for-service providers based on revenues from cost report data or revenue submissions. The Corporation received approximately \$620,000 in funding from this distribution.
- \$10 Billion Rural Distribution On May 6, 2020, HHS distributed \$10 billion to almost 4,000 rural health care providers including hospitals, health clinics, and health centers. The Corporation received approximately \$5,101,000 in funding from this distribution.
- \$4.9 Billion Allocation for Skilled Nursing Facilities (SNFs) On May 22, 2020, HHS distributed \$4.9 billion to over 13,000 certified SNFs based on a fixed payment of \$50,000 plus \$2,500 per certified bed. The Corporation received approximately \$708,000 in funding from this distribution.
- \$10 Billion High Impact Distribution On July 17, 2020, HHS distributed \$10 billion to more than 1,000 providers with over 160 COVID-19 admissions between January 1, 2020 and June 10, 2020 (one admission per day) or a disproportionate intensity of COVID-19 admissions. Payments were determined as \$50,000 per COVID-19 admission. The Corporation received approximately \$4,300,000 in funding from this distribution.
- \$2.5 Billion Allocation for SNFs On August 7, 2020, HHS distributed \$2.5 billion to over 15,000 certified SNFs based on a fixed payment of \$10,000 plus \$1,450 per certified bed. The Corporation received approximately \$372,000 in funding from this distribution.
- \$4.9 Million Small Rural Hospital Improvement Program (SHIP) Grant On April 22, 2020, HHS appropriated approximately \$4.9 million to the State of Georgia Department of Community Health, State Office of Rural Health to disburse to 58 rural hospitals in Georgia for the purpose of preventing, preparing for, and responding to COVID-19. The Corporation received approximately \$84,000 in funding from this grant.
- \$17 Billion General Distribution (4th Round) On December 16, 2021, HHS began distributing \$17 billion to providers based on changes in revenues and expenses as well as the amount and type of services provided to Medicare, Medicaid, and/or Children's Health Insurance Program patients. The Corporation received approximately \$423,000 in funding from this distribution.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

19. <u>Coronavirus, Continued</u>

In addition, the CARES Act did the following:

- Sequestration Suspended the Medicare sequestration payment adjustment, which reduces the payments to providers by 2%, for the period of May 1, 2020 through December 31, 2020. Subsequently, with the passing of the *Consolidated Appropriations Act, An Act to Prevent Across-the-Board Direct Spending Cuts, and for Other Purposes,* and *Protecting Medicare and American Farmers from Sequester Cuts Act,* the sequestration suspension was extended to March 31, 2022. Beginning April 1, 2022, the suspension is phased out through June 30, 2022.
- Medicare Add-on for Inpatient Hospital COVID-19 Patients Increase the Medicare payment for hospital patients admitted with COVID-19 by 20%.

On April 24, 2020, the Paycheck Protection Program and Health Care Enhancement Act was passed. This Act provides additional funding to replenish and supplement key programs under the CARES Act, including funds to health care providers for COVID-19 testing. The Corporation has received the following funding under this Act.

• \$225 Million Rural Health Clinic Distribution - On May 20, 2020, HHS distributed \$225 million to over 4,500 rural health clinics (RHCs) based on a fixed payment of \$49,461 per RHC. The Corporation received approximately \$148,000 in funding from this distribution.

On March 11, 2021, the *American Rescue Plan Act* (ARPA) was passed. This Act provides additional financial assistance for state and local governments, education, housing, food assistance, and additional grant programs. The Corporation received the following program funding related to this Act:

- \$425 Million Rural Health Clinic Distribution On June 10, 2021, HHS distributed \$425 million to over 4,200 RHCs for COVID-19 testing and mitigation based on a fixed payment of \$100,000 per RHC. The Corporation received approximately \$200,000 in funding from this distribution.
- \$7.5 Billion Rural Payment On November 23, 2021, HHS began distributing \$7.5 billion to nearly 44,000 rural providers that served Medicaid, Children's Health Insurance Program (CHIP), and Medicare beneficiaries from January 1, 2019 through September 30, 2020. The Corporation received approximately \$3,535,000 from this distribution.

The Authority also received various other grants in response to COVID-19 that totaled approximately \$1,595,000.

NOTES TO COMBINED FINANCIAL STATEMENTS, Continued June 30, 2022 and 2021

19. <u>Coronavirus, Continued</u>

The CARES Act and ARPA funding is a conditional contribution and accounted for as a refundable advance until conditions have been substantially met or explicitly waived by the grantor. Because the use of the funds is limited to the purposes stated in the terms and conditions, the contributions are grantor restricted. The Corporation reports restricted contributions, whose restrictions are met in the same period in which they are recognized (simultaneous release), as net assets without donor restrictions. Recognized revenue is reported as other operating revenue in the combined statements of operations and changes in net assets. The Corporation recognized approximately \$5,097,000 and \$5,186,000 in grant stimulus funding in fiscal years 2022 and 2021, respectively.

CARES Act and ARPA funding may be subject to audits. While the Corporation currently believes its use of the funds is in compliance with applicable terms and conditions, there is a possibility payments could be recouped based on changes in reporting requirements or audit results.

The CARES Act also expanded the existing Medicare Accelerated and Advance Payment Program (MAPP) by allowing qualifying providers to receive an advanced Medicare payment. The advance payment is a loan that will have to be repaid. Repayment begins one year after the date the MAPP funds were issued, at which time, Medicare payments owed to the Corporation will be recouped at varying rates ranging from 25% to 50% for 17 months. After 29 months, the remaining balance of the MAPP funds, if any, will become due in full. Providers will have 30 days to pay the remaining balance and if payment is not received, interest will accrue on the outstanding balance at a rate of 4%. The Corporation received total MAPP funds of approximately \$8,299,000 during fiscal years 2020 and 2021, and repaid approximately \$4,099,000 during 2022. INDEPENDENT AUDITOR'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS



INDEPENDENT AUDITOR'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

Board of Directors Crisp Regional Health Services, Inc. Cordele, Georgia

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the combined financial statements of Crisp Regional Health Services, Inc. (Corporation), which comprise the combined balance sheet as of June 30, 2022, and the related combined statements of operations and changes in net assets and cash flows for the year then ended, and the related notes to the combined financial statements, and have issued our report thereon dated October 25, 2022.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the combined financial statements, we considered the Corporation's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the combined financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control. Accordingly, we do not express an opinion on the effectiveness of the Corporation's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Continued

39

Let's Think Together.®

Draffin & Tucker, LLP | CPAs and Advisors | www.draffin-tucker.com P.O. Box 71309 | 2617 Gillionville Road | Albany, GA 31708-1309 | (229) 883-7878 5 Concourse Parkway, Suite 1250 | Atlanta, GA 30328 | (404) 220-8494 Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Corporation's combined financial statements are free from material misstatement, we performed tests of its compliance with the certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the combined financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Corporation's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Corporation's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

DRAFFIN + TUCKER, MP

Albany, Georgia October 25, 2022